Autres langues OSE Immunotherapeutics

Actions

OSE

FR0012127173

Temps réel Euronext Paris Autres places de cotation 09:43:46 25/04/2024			Varia. 5j.	Varia. 1 janv.
5,62 ^EUR	-0,35 %		+12,40 %	+31,31 %

22/04	Ose Immunotherapeutics : plus forte hausse du SRD à la clôture du lundi 22 avril 2024	AO
19/04	Ose Immunotherapeutics : plus forte hausse du SRD à la clôture du vendredi 19 avril 2024 -	AO

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

OSE Immunotherapeutics Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective	17/04
OSE : entrée en vigueur de l'accord de licence avec AbbVie	17/04
OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie	17/04
Bolsa de Madrid: El margen de maniobra de la Fed se reduce	17/04
OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective	16/04
OSE Immunotherapeutics SA's Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective	16/04
Global markets live: Airbus, UBS, KKR, Meta Platforms, Tesla...	11/04
Ose Immuno a reçu un financement de Bpifrance	11/04
Bolsa de Madrid: ¿Qué tan malo es, Dr. Powell?	11/04
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer	10/04
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer	10/04
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology	02/04
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update	27/03
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update	27/03
OSE Immunotherapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
OSE IMMUNOTHERAPEUTICS : Degroof Petercam réitère l'achat	18/03
OSE Immunotherapeutics : Inside Information / Other news releases	18/03
OSE Immuno : fin du recrutement d'un essai pour le RCH	18/03
OSE Immunotherapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial Evaluating Lusvertikimab in Patients with Ulcerative Colitis	18/03
Ose Immunotherapeutics Sa Announces Completion of Enrollment in Phase 2 Clinical Trial Evaluating Lusvertikimab in Patients with Ulcerative Colitis	18/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues OSE Immunotherapeutics

Actions

OSE

FR0012127173

Autres langues

Filtres